Drug Ads' Survival Hangs in Balance

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

Now that the Food and Drug Administration has said it will issue new guidelines for prescription-drug ads this fall, one option would be to eliminate the ads, according to a notice published in the Federal Register last week.

The FDA said it will hold a two-day public meeting Sept. 22 and 23 to study the latest research on direct-to-consumer ads for prescription drugs. At issue: whether such ads make consumers aware of potential life-threatening situations, as the pharmaceutical industry maintains, or drive up healthcare costs, as consumer groups and some lawmakers contend.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in